RT Journal
A1 Gibbons RD, Brown C, Hur K, Davis JM, Mann J
T1 INappropriate data and measures lead to questionable conclusions—reply
JF JAMA Psychiatry
JO JAMA Psychiatry
YR 2013
FD January 1
VO 70
IS 1
SP 121
OP 123
DO 10.1001/jamapsychiatry.2013.749
UL http://dx.doi.org/10.1001/jamapsychiatry.2013.749
AB 
Spielmans and colleagues state that study LYAQ included atomoxetine as a treatment and should have been excluded. In fact, the first 2 active treatment visits did not include atomoxetine and our analysis of the data from this study was restricted to this period (days 1-42 postbaseline depending on the subject). Furthermore, although patients in this study had comorbidities including attention-deficit/hyperactivity disorder, the majority (81%) of patients had a depressive disorder. As such, our inclusion of this study was scientifically appropriate.